Bristol-Myers to buy Celgene in a $74 billion deal


Daniel Acker | Bloomberg | Getty Images

Coumadin medication by Bristol-Myers Squibb on pharmacy shelf in Princeton, Illinois.

Celgene shares surged 32 percent in premarket trading on Thursday after Bristol-Myers Squibb announced plans to buy the cancer drugmaker in a cash and stock deal valued at $74 billion.

Under the agreement, Celgene shareholders will receive 1 Bristol-Myers Squibb share and $50 in cash for each share of Celgene.

Shares of Bristol-Myers Squibb were down more than 13 percent in premarket trading.

“Together with Celgene, we are creating an innovative biopharma leader, with leading franchises and a deep and broad pipeline that will drive sustainable growth and deliver new options for patients across a range of serious diseases,” Bristol-Myers Squibb Chairman and CEO Giovanni Caforio said in a press release.

The boards of directors of both companies approved the deal. The combined company will have nine products with more than $1 billion in annual sales and significant potential for growth in oncology, immunology and inflammation and cardiovascular disease.

Celgene was set to lose patent protection by 2022 for Revlimid, its top-selling multiple myeloma drug. Early last year, Celgene agreed to to buy the rest of Juno Therapeutics it didn’t already own for about $9 billion in cash to gain access to Juno’s pipeline of cancer drugs.

The company has been working on an experimental new gene therapy called CAR T-cell therapy — taking a patient’s own immune cells, called T cells, genetically manipulating them to attack specific proteins on cancer, and infusing them back into the patient.

This story is developing. Please check back for updates.

Source link

Products You May Like

Articles You May Like

Micron says memory chip recovery is coming later in the year, sending shares higher
Battery start-ups are raising millions in the battle to crush Tesla
Lyft gets its first buy recommendation and it’s not even public yet
Facebook has worst day of year on downgrade, investigations and exits
China needs better data privacy policy to capture digital trade growth

Leave a Reply

Your email address will not be published. Required fields are marked *